Yanan Zhu
Stock Analyst at Wells Fargo
(2.12)
# 2,979
Out of 5,090 analysts
84
Total ratings
37.14%
Success rate
-1.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Overweight | $80 → $60 | $23.09 | +159.85% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $17 → $12 | $9.77 | +22.89% | 7 | Nov 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $50 → $45 | $22.81 | +97.28% | 7 | Nov 5, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $48 → $72 | $34.40 | +109.30% | 7 | Nov 3, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $6.78 | +194.99% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.44 | +63.93% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $35.97 | +25.10% | 1 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $77 → $82 | $81.64 | +0.44% | 3 | Aug 22, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $16 → $12 | $1.80 | +568.52% | 4 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $7.5 → $8 | $5.06 | +58.10% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.11 | +126.24% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.57 | +218.47% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $2.22 | +530.63% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $71.53 | +4.85% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $29.01 | +141.30% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.34 | +130.41% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $33.55 | +19.23% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $58.85 | +10.45% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.18 | +266.75% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.54 | +646.97% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.64 | +12,262.64% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $916.31 | -64.42% | 1 | Feb 2, 2021 |
uniQure
Nov 12, 2025
Maintains: Overweight
Price Target: $80 → $60
Current: $23.09
Upside: +159.85%
Intellia Therapeutics
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $17 → $12
Current: $9.77
Upside: +22.89%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $22.81
Upside: +97.28%
RAPT Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $48 → $72
Current: $34.40
Upside: +109.30%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $6.78
Upside: +194.99%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.44
Upside: +63.93%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $35.97
Upside: +25.10%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $77 → $82
Current: $81.64
Upside: +0.44%
Metagenomi
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.80
Upside: +568.52%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Overweight
Price Target: $7.5 → $8
Current: $5.06
Upside: +58.10%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.11
Upside: +126.24%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.57
Upside: +218.47%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.22
Upside: +530.63%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $71.53
Upside: +4.85%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $29.01
Upside: +141.30%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $4.34
Upside: +130.41%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $33.55
Upside: +19.23%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $58.85
Upside: +10.45%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $8.18
Upside: +266.75%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.54
Upside: +646.97%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $3.64
Upside: +12,262.64%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $916.31
Upside: -64.42%